The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity
暂无分享,去创建一个
A. Kleijn | M. Lamfers | G. Fulci | S. Leenstra | R. Debets | C. Dirven | J. Kloezeman | Elike Treffers-Westerlaken
[1] K. Partanen,et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[2] K. Partanen,et al. Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus , 2013, Clinical Cancer Research.
[3] M. Willingham,et al. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus. , 2013, Surgery.
[4] J. Sarkaria,et al. Oncolytic measles virus strains have significant antitumor activity against glioma stem cells , 2012, Gene Therapy.
[5] M. Caligiuri,et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors , 2012, Nature Medicine.
[6] S. Sengupta,et al. Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy , 2012, Clinical & developmental immunology.
[7] I. McNeish,et al. Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo. , 2012, Molecular Therapy.
[8] J. Larkin,et al. Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies , 2012, Clinical Cancer Research.
[9] L. Hwang,et al. Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[10] S. Sengupta,et al. Mechanisms of immune evasion by gliomas. , 2012, Advances in experimental medicine and biology.
[11] E John Wherry,et al. T cell exhaustion , 2011 .
[12] R. Weissleder,et al. Distinguishing Inflammation from Tumor and Peritumoral Edema by Myeloperoxidase Magnetic Resonance Imaging , 2011, Clinical Cancer Research.
[13] M. Raffeld,et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] P. Marcato,et al. Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor Immunity , 2010, Molecular Cancer Therapeutics.
[15] Raymond D. Harris,et al. A Phase I Study of a Tropism-Modified Conditionally Replicative Adenovirus for Recurrent Malignant Gynecologic Diseases , 2010, Clinical Cancer Research.
[16] J. Verweij,et al. Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells , 2010, Cancer Immunology, Immunotherapy.
[17] M. Opp,et al. Lipopolysaccharide-induced increases in cytokines in discrete mouse brain regions are detectable using Luminex xMAP® technology , 2008, Journal of Neuroscience Methods.
[18] J. Sagartz,et al. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[19] N. Parameswaran,et al. Adenovirus Vector-Induced Innate Inflammatory Mediators, MAPK Signaling, As Well As Adaptive Immune Responses Are Dependent upon Both TLR2 and TLR9 In Vivo1 , 2008, The Journal of Immunology.
[20] F. Lang,et al. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[21] J. Fallon,et al. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[22] W. Vandertop,et al. Differential Effects of Combined Ad5-Δ24RGD and Radiation Therapy in In vitro versus In vivo Models of Malignant Glioma , 2007, Clinical Cancer Research.
[23] W. Yung,et al. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. , 2007, Cancer research.
[24] W. Vandertop,et al. AdΔ24 and the p53‐expressing variant AdΔ24‐p53 achieve potent anti‐tumor activity in glioma when combined with radiotherapy , 2007 .
[25] M. Magnusson,et al. An oncolytic adenovirus redirected with a tumor-specific T-cell receptor. , 2007, Cancer research.
[26] H. Colman,et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. , 2007, Journal of the National Cancer Institute.
[27] L. Boon,et al. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo , 2007, International journal of cancer.
[28] R. Vile,et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. , 2007, Cancer research.
[29] W. Vandertop,et al. AdDelta24 and the p53-expressing variant AdDelta24-p53 achieve potent anti-tumor activity in glioma when combined with radiotherapy. , 2007, The journal of gene medicine.
[30] Ralph Weissleder,et al. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[31] A. Kiang,et al. Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[32] M. Caligiuri,et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses , 2006, Proceedings of the National Academy of Sciences.
[33] H. Hamada,et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy , 2006, Cancer science.
[34] J. Gomori,et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[35] J. Cidlowski,et al. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. , 2005, The New England journal of medicine.
[36] D. Sze,et al. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin , 2005, Cancer Gene Therapy.
[37] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[38] J. Sloan,et al. Phase I–II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas , 2005, Gene Therapy.
[39] D. Muruve,et al. The innate immune response to adenovirus vectors. , 2004, Human gene therapy.
[40] J. Olson,et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[41] D. Pardoll,et al. Dexamethasone Mediated Inhibition of Local IL-2 Immunotherapy is Dose Dependent in Experimental Brain Tumors , 2004, Journal of Neuro-Oncology.
[42] D. Curiel,et al. Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer , 2004, International journal of cancer.
[43] R. Alemany,et al. Conditionally Replicative Adenovirus with Tropism Expanded towards Integrins Inhibits Osteosarcoma Tumor Growth in Vitro and in Vivo , 2004, Clinical Cancer Research.
[44] Jaap Goudsmit,et al. Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors , 2003, Journal of Clinical Microbiology.
[45] A. Pathak,et al. Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps. , 2003, Neuro-oncology.
[46] R. Cattaneo,et al. Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. , 2003, Cancer research.
[47] G. Fuller,et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. , 2003, Journal of the National Cancer Institute.
[48] W. Vandertop,et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. , 2002, Cancer research.
[49] D. Nettelbeck,et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. , 2002, Cancer research.
[50] R. Alemany,et al. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[51] Becky,et al. Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. , 2000, Journal of neurosurgery.
[52] R. Martuza,et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial , 2000, Gene Therapy.
[53] P. Lowenstein,et al. Interleukin-1 Mediates a Rapid Inflammatory Response After Injection of Adenoviral Vectors into the Brain , 1999, The Journal of Neuroscience.
[54] A. Houweling,et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. , 1996, Human gene therapy.
[55] S. Sierakowski,et al. Mechanism of action of glucocorticosteroids. Inhibition of T cell proliferation and interleukin 2 production by hydrocortisone is reversed by leukotriene B4. , 1986, The Journal of clinical investigation.